within Pharmacolibrary.Drugs.ATC.S;

model S01KA02
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01KA02</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Hypromellose (hydroxypropyl methylcellulose) is a semisynthetic, inert, viscoelastic polymer used primarily as an ocular lubricant in artificial tears for the treatment of dry eye syndrome. It is also used as a thickener and emulsifier in pharmaceutical formulations. It is approved for ophthalmic use and is commonly found in over-the-counter eye drops.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic (PK) parameters are reported in the published literature for hypromellose when used as an ophthalmic agent in humans, likely due to its minimal systemic absorption and local action on the ocular surface. The following values are estimates based on the drug’s physicochemical properties and typical usage.</p><h4>References</h4><ol><li><p>Maria, DN, et al., &amp; Jablonski, MM (2017). Nimodipine Ophthalmic Formulations for Management of Glaucoma. <i>Pharmaceutical research</i> 34(4) 809–824. DOI:<a href=\"https://doi.org/10.1007/s11095-017-2110-x\">10.1007/s11095-017-2110-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28155073/\">https://pubmed.ncbi.nlm.nih.gov/28155073</a></p></li><li><p>Long, Y, et al., &amp; He, N (2024). Design and Evaluation of Ophthalmic Thermosensitive In Situ Gel of Compound Salvia. <i>AAPS PharmSciTech</i> 25(7) 191–None. DOI:<a href=\"https://doi.org/10.1208/s12249-024-02913-8\">10.1208/s12249-024-02913-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39164556/\">https://pubmed.ncbi.nlm.nih.gov/39164556</a></p></li><li><p>Muankaew, C, et al., &amp; Loftsson, T (2016). Cyclodextrin-based telmisartan ophthalmic suspension: Formulation development for water-insoluble drugs. <i>International journal of pharmaceutics</i> 507(1-2) 21–31. DOI:<a href=\"https://doi.org/10.1016/j.ijpharm.2016.04.071\">10.1016/j.ijpharm.2016.04.071</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27139144/\">https://pubmed.ncbi.nlm.nih.gov/27139144</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01KA02;
